Sector News

Brexit ambition is ‘fine’ but execution is key, says Brexit Health Alliance

July 16, 2018
Life sciences

The co-chair of the Brexit Health Alliance, Niall Dickson, has welcomed the ambition of the government’s Brexit white paper but warned that execution will be key.

“The ambition is fine – but we await the execution,” said Dickson, who is Chief Executive of the NHS Confederation. “Patients in the UK and Europe need to know that they will get their drugs on time, that vital medical research will not be disrupted and that they will continue to get the healthcare they need while on holiday or travelling for work.”

“These are not theoretical possibilities, they are real risks which can and must be resolved in the negotiations. We have consistently called for assurances on all these matters and we welcome the government’s clear ambition to deal with them.

He added: “We also welcome the commitment to maintaining the highest standards of health protection after the UK leaves the EU. Maximum co-operation to control infectious diseases and other public health threats is a ‘no brainer’. But these are complex and wide-ranging negotiations and there is always a danger that health issues are not kept to the fore.

“We should be under no illusions of the consequences for patients if we fail to plan properly and do not reach a good agreement. That could result in a significant threat to the health of both UK and EU citizens.

“Planning is underway at the centre of government, but it will be important for the sake of patients that NHS hospitals, clinics and community services are all prepared for every possible scenario.”

The Brexit Health Alliance brings together the NHS, medical research, industry, patients and public health organisations, with the aim to safeguard the interests of patients and the healthcare and research they rely on during the Brexit negotiations.

The Alliance is working to ensure that issues such as healthcare research, access to technologies and treatment of patients are given the prominence and attention they deserve in the Brexit negotiations, and argues that it is in both Europe and the UK’s interests to maintain co-operation in research and in handling public health issues. It has also called on the UK government to make sure there is a commitment to medical research and providing alternative funding, and that UK citizens’ right to receive healthcare in EU countries is preserved.

By: George Underwood
Source: Pharma Times

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach